Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2001 1
2004 1
2005 3
2007 3
2008 4
2009 1
2010 5
2011 1
2012 1
2013 1
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Ultra-low dose naltrexone enhances cannabinoid-induced antinociception.
Paquette J, Olmstead MC. Paquette J, et al. Behav Pharmacol. 2005 Dec;16(8):597-603. doi: 10.1097/00008877-200512000-00001. Behav Pharmacol. 2005. PMID: 16286810
As opioid and cannabinoid systems interact, this study investigated whether ultra-low dose naltrexone also influences cannabinoid-induced antinociception. ...A high dose of naltrexone had no effect on WIN 55 212-2-induced tail flick laten …
As opioid and cannabinoid systems interact, this study investigated whether ultra-low dose naltrexone also influ …
Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats.
Mattioli TA, Milne B, Cahill CM. Mattioli TA, et al. Mol Pain. 2010 Apr 16;6:22. doi: 10.1186/1744-8069-6-22. Mol Pain. 2010. PMID: 20398374 Free PMC article.
In this study we demonstrate that ultra-low dose naltrexone attenuates glial activation, which may contribute to its effects on attenuating tolerance. ...Co-injection of ultra-low dose naltrexone attenuated this increase in …
In this study we demonstrate that ultra-low dose naltrexone attenuates glial activation, which may contribute to …
Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects.
Hay JL, La Vincente SF, Somogyi AA, Chapleo CB, White JM. Hay JL, et al. Eur J Pain. 2011 Mar;15(3):293-8. doi: 10.1016/j.ejpain.2010.07.009. Epub 2010 Aug 21. Eur J Pain. 2011. PMID: 20728384 Clinical Trial.
The aim of the current investigation was to determine whether buprenorphine antinociception could be enhanced with the addition of ultra-low dose naltrexone, using a range of dose ratios. ...These findings suggest that, as previously described w …
The aim of the current investigation was to determine whether buprenorphine antinociception could be enhanced with the addition of ultra
Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.
Webster LR. Webster LR. Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83. doi: 10.1517/13543784.16.8.1277. Expert Opin Investig Drugs. 2007. PMID: 17685875 Review.
Oxytrex (Pain Therapeutics, Inc.) is an oral opioid that combines a therapeutic amount of oxycodone with an ultra-low dose of the antagonist naltrexone. ...The putative mechanism of ultra-low-dose naltrexone is to prevent an …
Oxytrex (Pain Therapeutics, Inc.) is an oral opioid that combines a therapeutic amount of oxycodone with an ultra-low dose
Oxycodone combined with opioid receptor antagonists: efficacy and safety.
Davis M, Goforth HW, Gamier P. Davis M, et al. Expert Opin Drug Saf. 2013 May;12(3):389-402. doi: 10.1517/14740338.2013.783564. Epub 2013 Mar 28. Expert Opin Drug Saf. 2013. PMID: 23534906 Review.
AREAS COVERED: The authors cover the use of OXY plus ultra-low-dose naltrexone for analgesia and the use of sustained-release OXY plus sustained-release naloxone to reduce the opioid bowel syndrome. ...High attrition and marginal differences between …
AREAS COVERED: The authors cover the use of OXY plus ultra-low-dose naltrexone for analgesia and the use of sust …
Does adding low doses of oral naltrexone to morphine alter the subsequent opioid requirements and side effects in trauma patients?
Farahmand S, Ahmadi O, Dehpour A, Khashayar P. Farahmand S, et al. Am J Emerg Med. 2012 Jan;30(1):75-8. doi: 10.1016/j.ajem.2010.09.031. Epub 2010 Nov 13. Am J Emerg Med. 2012. PMID: 21075578 Clinical Trial.
METHODS: In the present randomized, double-blind controlled trial, the influence of the combination of ultra-low-dose naltrexone and morphine on the total opioid requirement and the frequency of the subsequent side effects was compared with that of mor …
METHODS: In the present randomized, double-blind controlled trial, the influence of the combination of ultra-low-dose
Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats.
Olmstead MC, Burns LH. Olmstead MC, et al. Psychopharmacology (Berl). 2005 Sep;181(3):576-81. doi: 10.1007/s00213-005-0022-7. Epub 2005 Oct 12. Psychopharmacology (Berl). 2005. PMID: 16010543
RATIONALE: Ultra-low-dose opioid antagonists enhance opiate analgesia and attenuate tolerance and withdrawal. OBJECTIVES: To determine whether ultra-low-dose naltrexone (NTX) coadministration alters the rewarding effects of opiates …
RATIONALE: Ultra-low-dose opioid antagonists enhance opiate analgesia and attenuate tolerance and withdrawal. OBJECTIVE …
Ultra-low dose naltrexone potentiates the anticonvulsant effect of low dose morphine on clonic seizures.
Honar H, Riazi K, Homayoun H, Sadeghipour H, Rashidi N, Ebrahimkhani MR, Mirazi N, Dehpour AR. Honar H, et al. Neuroscience. 2004;129(3):733-42. doi: 10.1016/j.neuroscience.2004.08.029. Neuroscience. 2004. PMID: 15541894
However, ultra-low dose naltrexone could not increase the maximal anticonvulsant effect of morphine (1-3 mg/kg), possibly due to a ceiling effect. The proconvulsant effects of morphine on seizure threshold were minimally altered by ultra-low
However, ultra-low dose naltrexone could not increase the maximal anticonvulsant effect of morphine (1-3 mg/kg), …
Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.
Tompkins DA, Lanier RK, Harrison JA, Strain EC, Bigelow GE. Tompkins DA, et al. Psychopharmacology (Berl). 2010 Jul;210(4):471-80. doi: 10.1007/s00213-010-1838-3. Epub 2010 Apr 13. Psychopharmacology (Berl). 2010. PMID: 20386884 Free PMC article. Clinical Trial.
OBJECTIVE: Preclinical and clinical studies have shown that opioids combined with ultra-low-dose naltrexone (NTX) may have increased analgesic potency and have suggested reduced abuse or dependence liability. This study addressed whether addition of …
OBJECTIVE: Preclinical and clinical studies have shown that opioids combined with ultra-low-dose naltrexone (NTX …
PTI-609: a novel analgesic that binds filamin A to control opioid signaling.
Burns LH, Wang HY. Burns LH, et al. Recent Pat CNS Drug Discov. 2010 Nov;5(3):210-20. doi: 10.2174/157488910793362386. Recent Pat CNS Drug Discov. 2010. PMID: 20726836 Review.
PTI-609 was designed after discovering filamin A as the high-affinity target of naltrexone or naloxone. Combined with opiates, ultra-low-dose naloxone or naltrexone can enhance and prolong the analgesia of the opiate alone and prevent or attenua …
PTI-609 was designed after discovering filamin A as the high-affinity target of naltrexone or naloxone. Combined with opiates, ult
20 results
Jump to page
Feedback